Small numbers, big challenges: The complexities of economic modelling for rare diseases
Misti Paul, Analytics Director, explores some of the reasons why economic modelling of rare diseases is so challenging.
Rare diseases are a big area of investment for pharma, because of the lower costs of R&D, accelerated drug approval process, longer patent life and pricing incentives. However, economic modelling can be very challenging. The problem with rare diseases starts with defining what one is. In Europe, a rare disease is one that affects less than one person per 2000. The European Commission defines an ultra-orphan disease as one that affects less than one person in 50,000. In the US, a rare disease is defined by the FDA as one affecting fewer than 200,000 people. However, beyond market definitions, the challenges of economic modelling of these rare diseases are immense.
3 trends the healthcare market research industry should watch out for over the next decade
As we head into the 2020s, Associate Director Ellie Forde considers the key trends that might impact healthcare over the next 10 years and the possible impacts on market research.
My colleague Rachel Howard wrote a blog at the end of last year reviewing her predictions in 2010 for the coming decade. As we head into the 2020s, I thought it might be timely to consider the key trends that might impact healthcare over the next 10 years. With technology advancing at an ever-increasing pace, these may be many, but I want to focus on what I believe are three of the big ‘watch outs’, and those I am personally excited about.
How we evaluated the potential for an existing AI product to treat a rare disease
Our client had an existing product in the market for the treatment of an autoimmune condition and wished to explore the opportunities for using this drug to treat another more low-prevalence orphan disease where there is no current targeted treatment available. The client wished to determine the market potential for the existing drug and the challenges they may face.